Literature DB >> 24353682

Association between Polymorphisms in IL-16 Genes and Coronary Heart Disease risk.

Tan Hai-Feng1, Wang Wei2, Yang Yuan-Yuan3, Zhao Jun4, Gong Su-Ping5, Li Hui-Ming6.   

Abstract

OBJECTIVE: We aimed to investigate the role of polymorphisms in IL-16 genes on the susceptibility of Coronary Artery Disease (CAD).
METHODS: A total of 260 CAD cases and 281 health controls were collected between January 2008 and November 2011. Genotyping of IL-16 rs8034928, rs3848180, rs1131445, rs4778889 and rs11556218 was conducted by polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry technologies.
RESULTS: The frequencies of rs8034928 C allele and rs3848180 G allele in the CAD cases in CAD group were significantly higher than in controls. Compared with rs8034928 T/T genotype, a significant higher risk of CAD was found in C/C genotype (OR=1.87, 95%CI=1.17-3.03), and variant of rs8034928 showed a significant increased risk of CAD in dominant (OR=1.48, 95%CI=1.04-2.10) and recessive model (OR=1.70, 95%CI=1.10-2.67). The rs3848180 G/G was found to be associated with risk of CAD(OR=1.79, 95%CI=1.16-2.75), and G allele carries had a significant risk of CAD (OR=1.47, 95%CI=1.02-2.13).
CONCLUSIONS: Our study indicated that rs8034928 and rs11556218 polymorphisms are associated with CAD risk in a Chinese population, and IL-16 gene polymorphisms may be used as a predictor to the susceptibility of CAD.

Entities:  

Keywords:  Coronary artery disease; IL-16; Polymorphism; Predictor

Year:  2013        PMID: 24353682      PMCID: PMC3817778          DOI: 10.12669/pjms.294.3650

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


INTRODUCTION

Coronary artery disease (CAD) is a serious national health problem both in developed and developing country.[1] CAD is considered to be caused by various factors, such as inflammation, smoking, hypertension, diabetes and genetic factors.[2],[3] It is reported that the underlying pathological process of CAD is atherosclerosis, and atherosclerosis is a chronic inflammation induced by the deposit of oxidized lipids on the inner layer of the arterial wall.[3] Previous studies have shown that many inflammation related genes, such as interlukin-16 (IL-16) and interlukin-6 (IL-6), are susceptible to the risk of CAD.[4] Interleukin-16 (IL-16) is a proinflammatory and immunoregulatory cytokine, and is reported to be related with the inflammation and immunity.[3] IL-16 is a T-cell chemoattractant factor, and located on chromosome 15q26.3 and translated into a 631-amino acid precursor protein.[5] Several recent studies have shown the variants of IL-16 gene are associated with various cancers risk and autoimmune diseases, such as rs11556218 and rs3848180.[6]-[8] Previous study has indicated that the levels of IL-6 and its final product, C reactive protein, have been associated with increased CAD risk.[9] The polymorphism of this gene could increase the concentration of IL-6 in plasma and CRP levels, and thus increase the inflammation process and blood pressure. However, the results are inconsistent.[3],[9],[10] Two previous studies reported the negative association between polymorphisms of IL-6 and risk of CAD. [9],[10] Therefore, the present study was aimed to investigate the role of polymorphism in IL-16 (rs8034928, rs3848180, rs1131445, rs4778889 and rs11556218) on the susceptibility of CAD in a case-control study.

METHODS

: This case-control study enrolled 260 CAD cases and 281 health controls. 308 patients were first diagnosed from January 2008 to November 2011 at the Second People’s Hospital of Ji’nan. The diagnosis of CAD was based on angiographic evidence of ≥70% stenosis of one major coronary artery and/or≥50% of the left main coronary artery. Initially, a total of 287 patients were collected, and 260 patients agreed to participate in our study, with a participation rate of 90.6%. A total of 313 controls who received a regular health examination were included into control group. Finally, 281 controls were enrolled in our study, with a participation rate of 89.9%. Controls with known CAD or other heart disease were excluded. This study was approved by the ethics committee of the Second People’s Hospital of Ji’nan, and written informed consent was obtained from all the cases and controls. All patients were asked to provide 5 ml venous blood. All candidate loci of IL-16 for tag single nucleotide polymorphisms (SNPs) in the NCBI dbSNP database and SNP info. We selected common variants with the minor allele frequency should ≥10% of the Chinese population, and the SNP could influence the microRNA binding sites activity. Finally five SNPs, rs8034928, rs3848180, rs1131445, rs4778889 and rs11556218, were selected. The genomic DNA was extracted by the method of buffy-coat fractions with TIANamp blood DNA kit (Tiangen Biotech, Beijing, China). Genotyping of rs8034928, rs3848180, rs1131445, rs4778889 and rs11556218 was performed in a 384-well plate format on the Sequenom MassARRAY platform (Sequenom, San Diego, USA), and methods of polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry technologies. The ingle base extension (SBE) and PCR primers were designed using Sequenom Assay Design 3.1 software (Sequenom, San Diego, CA, USA) (Table-I). Each PCR reaction was carried out with a volume of 20 μl containing 50ng of genomic DNA, 200μM dNTP, 2.5 units of Taq DNA polymerase, and 200μM primers. The cycling programme of PCR reaction was preliminary denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, annealing temperature reduced to 64°C for 30 s, and 72°C for 10 min. PCR product was testified by on 1.0% agrose gel electrophoresis. A repeat analysis of a randomly chosen subgroup of 10% of the cases and controls was conducted for quality control, and the reproducibility was 100%.
Table-I

PCR amplification primers and restriction enzymes

IL-16 SNP Forward primer Reverse primer
rs80349285´-TTCCATTTGAAGAGAGC-3´5´-TGCAGAAAACCCAGGTTC-3´
rs38481805´-CCTCCAGTTCACAGCATCA-3´5´-GCTCTACGTTAGTTCCCTTA-3´
rs11314455´-TTGATGTTGGCTGGGAACT-3´5´-CACGCTTTGAGCTTGGTG-3´
rs47788895´-CTCCACACTCAAAGCCTTT-3´5´-CCATGTCAAAACGGTAGCCT-3´
rs115562185´-CTCAGGTTCACAGAGTGT-3´5´-TGTGACAATCACAGCTTGCC-3´
PCR amplification primers and restriction enzymes Continuous variables were shown as mean±SD and analyzed by students t test. Categorical variables were expressed as frequency and percentage and analyzed by chi-square test. The Hardy-Weinberg equilibrium and genotype distributions between groups were analyzed using chi-square test. Odds ratios (OR) and the corresponding 95% confidence intervals (CI) were taken to evaluate the effect of IL-16 (rs8034928, rs3848180, rs1131445, rs4778889 and rs11556218) on the risk of CAD. Multivariable logistic regression analysis was conducted to calculate the OR (95% CI) after adjusting for potential confounding factors of CAD, such as sex, smoking, BMI, hypertension, diabetes, TC, TG, LDL-C and HDL-C. All statistical analyses were conducted by SPSS 11.0 software (SPSS, Chicago, IL), and P value<0.05 was regarded as statistically significant.

RESULTS

This study included 260 CAD cases (172 males and 88 females, mean age of 63.1±7.8 years, range 42 to 79 years) and 281 health controls (152 males and 129 females, mean age of 62.4±8.5 years, range 40 to 74 years) (Table-II). Compared with the controls, the CAD patients were more likely to be male, had older age, higher BMI and hypertension, and higher proportion of smoking status and diabetes (P<0.05 for all comparisons). The control group had significantly higher TC, HDL-C and LDL-C levels when compared with CAD patients.
Table-II

The clinical characteristics between CAD patients and controls

Variables Cases, n % Controls, n % P value
Age (years)63.1±7.862.4±8.50.1
Sex (%)
  Male17266.2152 54.2<0.05
  Female88 33.812945.8
BMI (kg/m2)23.4±3.222.5±2.6<0.05
Smoking (%)
  Ever103 39.586 30.6
  Never157 60.5195 69.4<0.05
Diabetes (%)
  Yes108 41.755 19.7
  No152 58.3226 80.3<0.05
Hypertension (%)
  Yes85 32.860 21.2
  No175 67.2221 78.8<0.05
TC(mmol/L)4.1±1.24.6±1.3<0.05
TG(mmol/L)2.0±1.21.7±1.0<0.05
LDL-C(mmol/L)2.6±1.12.9±0.8<0.05
HDL-C(mmol/L)1.2±0.41.5±0.4<0.05
The clinical characteristics between CAD patients and controls The genotype distributions of the five SNPs were shown in Table-III. The minor allele frequencies of IL-16 rs8034928, rs3848180, rs1131445, rs4778889 and rs11556218 in controls were in line with the published MAFs (http://www.ncbi.nlm.nih.gov/snp/) and the Hardy-Weinberg equilibrium. The IL-16 rs8034928 and rs3848180 genotype frequencies showed significantly difference between the two groups, and the IL-16 rs8034928 C allele and rs3848180 G allele frequencies were significantly higher in CAD patients than controls (57.7% vs 48.1% for rs8034928 C allele; 67.7% vs 58.7% for rs3848180 G allele) (Fig. 1 and 2). However, there was no significant difference between the genotype frequencies of IL-16 rs1131445, rs4778889 and rs11556218 (P>0.05).
Table-III

Distribution of IL-16 genes polymorphisms between CAD cases and controls

IL-16 SNP Major/Minor allele MAF in PubMed Minor frequencies
CAD cases, n
Controls, n
P value
Case Control A/A 1 A/a 2 a/a 3 A/A A/a a/a
rs8034928T/C0.327 0.414 0.324 110 85 65 146 89 46 <0.05
rs3848180T/G0.477 0.446 0.428 84 79 97 116 90 75 <0.05
rs1131445T/C0.346 0.367 0.346 120 90 50 137 95 50 0.83
rs4778889C/T0.315 0.297 0.301 139 89 33 151 91 39 0.87
rs11556218G/T0.211 0.204 0.210 175 64 21 191 63 28 0.67

1. Wild-type; 2. Heterozygous variant; 3. Homozygous variant

Fig.1

Genotype frequencies of rs8034928

Fig.2

Genotype frequencies of rs3848180

Distribution of IL-16 genes polymorphisms between CAD cases and controls 1. Wild-type; 2. Heterozygous variant; 3. Homozygous variant Genotype frequencies of rs8034928 Genotype frequencies of rs3848180 Multivariate logistic regression analysis was taken to analyze the effect of IL-16 rs8034928 and rs3848180 polymorphisms on the CAD risk, adjusted for sex, BMI, smoking, diabetes, hypertension, TC, HDL-C, LDL-C and TG. The IL-16 rs8034928 C/C genotype showed a significant increased risk of CAD in codominant mode (OR=1.87, 95%CI=1.17-3.03), and the variant of IL-16 rs8034928 showed a significant increased risk of CAD in dominant (OR=1.48, 95%CI=1.04-2.10) and recessive model (OR=1.70, 95%CI=1.10-2.67). For polymorphism of IL-16 rs3848180, the IL-16 rs3848180 G/G genotype showed increased risk of CAD after adjusting potential risk factors (OR=1.79, 95%CI=1.16-2.75), and G allele genotype was associated with increased CAD risk in dominant model (OR=1.47, 95%CI=1.02-2.13). Association between polymorphisms in IL-6 and IL-16 and CAD risk 1. Adjusted for sex, BMI, smoking, diabetes, hypertension, TC, HDL-C, LDL-C and TG The combined effect of IL-16 rs8034928 and rs3848180 on the CAD risk was analyzed by multivariate logistic regression analysis, adjusted for sex, BMI, smoking, diabetes, hypertension, TC, HDL-C, LDL-C and TG. Individuals carrying both IL-16 rs8034928 C allele and rs3848180 T/T genotypes significantly increased the risk of CAD when compared with those carrying both IL-16 rs8034928 T/T and rs3848180 T/T genotypes (OR=2.31, 95% CI=1.24-4.32). Moreover, individuals with both IL-16 rs8034928 T/T and rs3848180 G allele genotypes had a significant increased risk of CAD than double wild-type genotypes (OR=2.02, 95% CI=1.18-3.45). Combined effect of rs8034928 and rs3848180 on the CAD risk 1. Adjusted for sex, BMI, smoking, diabetes, hypertension, TC, HDL-C, LDL-C and TG

DISCUSSION

In the present study, we have found that variants of IL-16 rs8034928 and rs3848180 may be associated with CAD risk in a Chinese population. Our study suggests that IL-16 rs8034928 and rs3848180 polymorphisms may influence the susceptibility to CAD risk. Recently, the identification of novel genetic variants for evaluating the early risk of CAD is attracting increasing interest of investigators on cancer risk worldwide. Based on the genetic information, we could determine the disease etiology in terms of genetic determinants to be used for identifying the high-risk individuals and perform targeting therapy to the individual’s genetic make-up.[11] It is reported that IL-16 gene consists of 7 exons and 6 introns convering approximately 12.8kb of genomic DNA.[12] The polymorphisms of IL-16 rs8034928 and rs3848180 polymorphisms are located on the intron region, and thus the polymorphisms could influence the susceptibility of human disease. Previous studies have reported that polymorphism of IL-16 rs11556218 and rs8034928 T/C are associated with various human cancers, such as allergic contact dermatitis, systemic lupus erythematosus, nasopharyngeal carcinoma and renal cell carcinoma.[6]-[8],[13] Previous two studies have shown that polymorphisms of IL-16 rs11556218 and rs8034928 are associated with risk of CAD.[14],[15] A study conducted in China with 651 CAD patients and 428 health controls has showed that rs8034928 C/C genotype is associated with a significant increased risk of CAD in a Chinese population, with the OR(95% CI) of 1.33(1.15-1.47).[14] In additionally, this study has shown that haploptypes TTTT and TGGT of IL-16 rs8034928, rs3848180 and rs1131445 significantly increased risk to CAD, whereas haplotypes of CTTT and TTGT referred to protection of CAD.[14] Similarly, we have found that IL-16 rs8034928 polymorphism is associated with a higher risk of CAD in our study, which is in line with previous reports.[14],[15] A recent study has shown that intronic sequences encode microRNAs, which are associated with RNA-mediated gene silencing.[16] This study has shown that IL-16 rs8034928 T/C polymorphism is in linkage disequilibrium with other casual genetic variants.[16] In our study, we found that IL-16 rs8034928 T/C polymorphism could influence the risk of CAD. Huang has reported that IL-16 rs3848180 polymorphism is associated with risk of CAD, and the rs3848180 polymorphism may influence IL-16 rs8034928 gene expression.[14] The results of our study also support the association between polymorphism of IL-16 rs8034928 and CAD risk. Further confirmation of our results is strongly needed in future studies. There are several limitations in our study. Firstly, the subjects were collected in a single hospital, and the samples could not well represent all the other populations. Secondly, CAD is a disease induced by multiple genes and environmental factors, and more genetic and environmental factors should be considered in further study. In conclusion, our study indicates that the variants of IL-16 rs8034928 and rs3848180 are associated with risk of CAD. However, we did not find statistically association of polymorphisms in rs1131445, rs4778889 and rs11556218 of IL-16 gene with CAD risk. The IL-16 gene polymorphisms may be used as a predictor to the susceptibility of CAD.

Authors Contributions:

THF & WW designed and performed the study, did statistical analysis & editing of manuscript. YYY, ZJ, GSP & LHM did data collection and manuscript writing.
Table-IV

Association between polymorphisms in IL-6 and IL-16 and CAD risk

IL-16 SNP Minor allele frequencies
OR (95% CI) 1
Cases % Controls % Codominant Dominant Recessive
rs8034928T/T11042.314652.0---
T/C8532.78931.71.27(0.85-1.90)1.48(1.04-2.10)1.70(1.10-2.67)
C/C6525.04616.41.87(1.17-3.03)
rs3848180T/T8432.311641.3-
T/G7930.49032.01.21(0.79-1.87)1.47(1.02-2.13)1.09(0.76-1.57)
G/G9737.37526.71.79(1.16-2.75)

1. Adjusted for sex, BMI, smoking, diabetes, hypertension, TC, HDL-C, LDL-C and TG

Table-V

Combined effect of rs8034928 and rs3848180 on the CAD risk

IL-16 SNP
Cases % Controls % OR (95% CI) 1
rs8034928 rs3848180
T/TT/T4216.28128.8-
C alleleT/T4216.23512.52.31(1.24-4.32)
T/TG allele6826.26523.12.02(1.18-3.45)
C alleleG allele10841.412635.61.56(0.93-2.67)

1. Adjusted for sex, BMI, smoking, diabetes, hypertension, TC, HDL-C, LDL-C and TG

  16 in total

1.  The gene encoding mouse interleukin-16 consists of seven exons and maps to chromosome 7 D2-D3.

Authors:  N Bannert; R Kurth; M Baier
Journal:  Immunogenetics       Date:  1999-07       Impact factor: 2.846

2.  Editorial comment to IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population.

Authors:  Wataru Obara
Journal:  Int J Urol       Date:  2010-08       Impact factor: 3.369

Review 3.  Intron-derived microRNAs--fine tuning of gene functions.

Authors:  Shao-Yao Ying; Shi-Lung Lin
Journal:  Gene       Date:  2004-11-10       Impact factor: 3.688

4.  Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping.

Authors:  H S Kim
Journal:  Cytogenet Cell Genet       Date:  1999

5.  No association of interleukin-6 gene polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors.

Authors:  Wolfgang Lieb; Robert Pavlik; Jeanette Erdmann; Bjoern Mayer; Stephan R Holmer; Marcus Fischer; Andrea Baessler; Christian Hengstenberg; Hannelore Loewel; Angela Doering; Guenter A Riegger; Heribert Schunkert
Journal:  Int J Cardiol       Date:  2004-11       Impact factor: 4.164

6.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina
Journal:  Eur Heart J       Date:  2007-08-28       Impact factor: 29.983

7.  Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma.

Authors:  Lin-Bo Gao; Wei-Bo Liang; Hui Xue; Li Rao; Xin-Min Pan; Mei-Li Lv; Peng Bai; Wen-Liang Fang; Jin Liu; Miao Liao; Lin Zhang
Journal:  Clin Chim Acta       Date:  2009-09-14       Impact factor: 3.786

8.  The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.

Authors:  Markus Nauck; Bernhard R Winkelmann; Michael M Hoffmann; Bernhard O Böhm; Heinrich Wieland; Winfried März
Journal:  J Mol Med (Berl)       Date:  2002-06-21       Impact factor: 4.599

9.  The association of interleukin-16 gene polymorphisms with susceptibility of coronary artery disease.

Authors:  Hao Huang; Zhi Zeng; Li Zhang; Rui Liu; Xian Li; Ou Qiang; Qing Zhang; Yucheng Chen
Journal:  Clin Biochem       Date:  2012-11-27       Impact factor: 3.281

10.  The effect of doubling the statin dose on pro-inflammatory cytokine in patients with triple-vessel coronary artery disease.

Authors:  Yoo Ri Kim; Jae Hong Park; Hye-Jin Lee; Wouk Bum Pyun; Si-Hoon Park
Journal:  Korean Circ J       Date:  2012-09-27       Impact factor: 3.243

View more
  3 in total

1.  Genetic polymorphisms of interleukin-16 and risk of knee osteoarthritis.

Authors:  Shi-Xing Luo; Shan Li; Xue-Hui Zhang; Jun-Jing Zhang; Guang-Hua Long; Gui-Fu Dong; Wei Su; Yan Deng; Yanqiong Liu; Jin-Min Zhao; Xue Qin
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

2.  Association of IL-16 gene polymorphisms with the risk of developing type 2 diabetes mellitus in the Chinese Han population.

Authors:  Fangxiao Cheng; Lu Liu; Hongli Zhang; Yi Zhu; Xiaohua Li; Hong Li
Journal:  Biosci Rep       Date:  2019-08-15       Impact factor: 3.840

3.  Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis.

Authors:  Victor Hugo de Souza; Josiane Bazzo de Alencar; Bruna Tiaki Tiyo; Hugo Vicentin Alves; Evelyn Castillo Lima Vendramini; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Oncotarget       Date:  2020-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.